Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Translational Research In Oncology.

    Client Virtual Booth

    TRANSLATIONAL RESEARCH IN ONCOLOGY

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Translational Research In Oncology
    Canada Flag
    Country
    Country
    Canada
    Address
    Address
    Suite 1100 9925-109 Street Edmonton, AB
    Telephone
    Telephone
    (780) 702 - 0200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.trioncology.org/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/trio---translational-research-in-oncology/
    Twitter
    Twitter
    https://twitter.com/TRIOncology

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Novartis Kisqali® Phase III NATALEE Trial Meets Primary Endpoint at Interim Analysis Demonstrating Clinically Meaningful Benefit in Broad Population of...

    Details:

    Kisqali® (ribociclib) is the only USFDA approved category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with HR+/HER2- MBC when combined with an AI.


    Lead Product(s): Ribociclib,Anastrozole

    Therapeutic Area: Oncology Product Name: Kisqali

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Novartis Kisqali® Adds One More Year of Survival Benefit for Broadest Set of Patients, Including Those With Aggressive HR+/HER2- Advanced Breast Cancer

    Details:

    Kisqali (ribociclib) is a unique CDK4/6 inhibitor, consistently demonstrating statistically significant OS benefit while maintaining or improving quality of life across three Phase III trials, regardless of patient or disease characteristics.


    Lead Product(s): Ribociclib,Fulvestrant

    Therapeutic Area: Oncology Product Name: Kisqali

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: Novartis Pharmaceuticals Corporation

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 09, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    TRIO Enrols First Patient in Global Phase 3 Giredestrant Early Breast Cancer Trial

    Details:

    Giredestrant is an oral selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging anti-tumour activity both alone and in combination with palbociclib in estrogen-receptor positive (ER+) metastatic breast cancer patients.


    Lead Product(s): Giredestrant,Palbociclib

    Therapeutic Area: Oncology Product Name: GDC-9545

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 31, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule

    Details:

    Giredestrant is an oral selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging tumour activity both alone and in combination with palbociclib in estrogen-receptor positive (ER+) metastatic breast cancer patients.


    Lead Product(s): Giredestrant,Palbociclib

    Therapeutic Area: Oncology Product Name: GDC-9545

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 06, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial

    Details:

    Ribociclib belongs to a class of targeted therapies called CDK4/6 inhibitors. Cyclin-dependent kinases 4 and 6 are proteins that help regulate cell replication and proper cell cycle function.


    Lead Product(s): Ribociclib,Fulvestrant

    Therapeutic Area: Oncology Product Name: Kisqali

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 21, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search